الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 127 |  |  |
| | | from | 127 | | |
Abstract
Background: Sestrin-2 (Sesn2) belongs to a family of highly conserved antioxidant proteins transcriptionally regulated by tumor suppressor p53, the most commonly mutated gene in cancers.
Objectives: The aim of this study was to assess the levels of Sesn2 in malignant pleural effusions of lung cancer patients compared to benign pleural effusions.
Patients and Methods: The study was conducted on 70 patients, 35 patients were diagnosed as benign pleural effusion and the other 35 patients were diagnosed as malignant pleural effusion.
Results: There was highly significant statistical level of sestrin 2 in malignant effusion when compared to benign effusion, while there was no significant statistical difference between malignant and benign effusion regarding LDH level. The cut off point of sestrin2 to differentiate between malignant and benign pleural effusion is 6 with sensitivity 100.0%, specificity 100.0%, PPV 100.0% and NPV 100.0%.
Conclusion: Sestrin 2 is a useful marker to differentiate between benign and malignant pleural effusion. There is no correlation between pleural fluid LDH, a surrogate marker of cell death, and Sestrin 2 suggesting that Sesn2 is not released into the pleural fluid due to cell death.